Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Melanoma

Journal Scan / Research · May 06, 2021

Early Discontinuation of PD-1 Blockade for Advanced Melanoma After a Complete or Partial Response

BMC Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

BMC Cancer
Early Discontinuation of PD-1 Blockade Upon Achieving a Complete or Partial Response in Patients With Advanced Melanoma: The Multicentre Prospective Safe Stop Trial
BMC Cancer 2021 Mar 25;21(1)323, EEAP Mulder, K de Joode, S Litière, AJ Ten Tije, KPM Suijkerbuijk, MJ Boers-Sonderen, GAP Hospers, JWB de Groot, AJM van den Eertwegh, MJB Aarts, D Piersma, RS van Rijn, E Kapiteijn, G Vreugdenhil, FWPJ van den Berkmortel, EO Hoop, MG Franken, B Ryll, P Rutkowski, S Sleijfer, JBAG Haanen, AAM van der Veldt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading